肿瘤患者肌肉减少症的诊治进展

doi:10.16689/j.cnki.cn11-9349/r.2020.02.022

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (442 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Abnormal metabolism in tumor patients， known as the metabolic reprogramming of tumor is one of the key characteristics of tumorigenesis. The rapid-growth tumor is compelled to compete for more nutrient. The need for high energy and low-energy aerobic glycolysis allow the body’s functional proteins to be used as energy， making it difficult to meet the normal physiological needs of patients. The complex nutritional metabolism of tumors and excessive protein consumption can reduce muscle mass and impair muscle function in cancer patients. The initial research of our team found that postoperative fatigue syndrome generally occurs in patients with abdominal tumors， and skeletal muscle function was significantly decreased after undergoing perioperative fasting and gastrointestinal surgery remodeling. Further clinical studies indicated that sarcopenia is an independent predictor of prognosis in patients with gastrointestinal tumors regardless of nutritional risk. Therefore， sarcopenia is an important concern for tumor patients during the perioperative period. It is of great clinical significance to include the diagnostic standard of sarcopenia in routine screening for tumor patients before surgery. It would enhance recovery after surgery and improve clinical outcomes if proper clinical interventions were carried out for the tumor patients with sarcopenia， and it would improve the life quality of tumor patients and reduce healthcare costs.

Key words： Sarcopenia Tumor Metabolic Prognosis

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Zou Hongbo
	Yan Xialin
	Yu Dingye
	Yu Zhen

Cite this article:

Zou Hongbo,Yan Xialin,Yu Dingye, et al. Research progress on diagnosis and treatment of sarcopenia in tumor patients[J]. Electron J Metab Nutr Cancer, 2020, 7(2): 250-254.

URL:

http://182.92.200.144/EN/10.16689/j.cnki.cn11-9349/r.2020.02.022 OR http://182.92.200.144/EN/Y2020/V7/I2/250

1.DE BARI L， ATLANTE A. Including the mitochondrial metabolism of L-lactate in cancer metabolic reprogramming［J］. Cell Mol Life Sci， 2018， 75（15）: 2763-2776.
2.MARTINEZ-OUTSCHOORN U E， PEIRIS-PAGES M， PESTELL R G， et al. Cancer metabolism: a therapeutic perspective［J］. Nat Rev Clin Oncol， 2017， 14（1）: 11-31.
3.HEINDEL J J， BLUMBERG B， CAVE M， et al. Metabolism disrupting chemicals and metabolic disorders［J］. Reprod Toxicol， 2017， 68: 3-33.
4.LU W， CAO F， WANG S， et al. LncRNAs: The regulator of glucose and lipid metabolism in tumor cells［J］. Front Oncol， 2019， 9: 1099.
5.LI Z， ZHANG H. Reprogramming of glucose， fatty acid and amino acid metabolism for cancer progression［J］. Cell Mol Life Sci， 2016， 73（2）: 377-392.
6.BOENGLER K， KOSIOL M， MAYR M， et al. Mitochondria and ageing: role in heart， skeletal muscle and adipose tissue［J］. J Cachexia Sarcopenia Muscle， 2017， 8（3）: 349-369.
7.CRUZ-JENTOFT A J， BAHAT G， BAUER J， et al. Sarcopenia: revised European consensus on definition and diagnosis［J］. Age Ageing， 2019， 48（1）: 16-31.
8.CHEN X Y， LI B， MA B W， et al. Sarcopenia is an effective prognostic indicator of postoperative outcomes in laparoscopic-assisted gastrectomy［J］. Eur journal surg oncol， 2019， 45（6）: 1092-1108.
9.ZHUANG C L， HUANG D D， PANG W Y， et al. Sarcopenia is an independent predictor of severe postoperative complications and long-term survival after radical gastrectomy for gastric cancer: analysis from a large-scale cohort［J］. Medicine （Baltimore）， 2016， 95（13）: e3164.
10.HUANG D D， ZHOU C J， WANG S L， et al. Impact of different sarcopenia stages on the postoperative outcomes after radical gastrectomy for gastric cancer［J］. Surgery， 2017， 161（3）: 680-693.
11.HUANG D D， WANG S L， ZHUANG C L， et al. Sarcopenia， as defined by low muscle mass， strength and physical performance， predicts complications after surgery for colorectal cancer［J］. Colorectal Dis， 2015， 17（11）: 256-264.
12.MA B W， CHEN X Y， FAN S D， et al. Impact of sarcopenia on clinical outcomes after radical gastrectomy for patients without nutritional risk［J］. Nutrition， 2019， 61: 61-66.
13.von Haehling S， Morley J E， Anker S D. An overview of sarcopenia: facts and numbers on prevalence and clinical impact［J］. J Cachexia Sarcopenia Muscle， 2010， 1（2）: 129-133.
14.ZHOU C J， ZHANG F M， ZHANG F Y， et al. Sarcopenia: a new predictor of postoperative complications for elderly gastric cancer patients who underwent radical gastrectomy［J］. J Surg Res， 2017， 211: 137-146.
15.HUANG D D， CHEN X X， CHEN X Y， et al. Sarcopenia predicts 1-year mortality in elderly patients undergoing curative gastrectomy for gastric cancer: a prospective study［J］. J Cancer Res Clin Oncol， 2016， 142（11）: 2347-2356.
16.KOBAYASHI A， KAIDO T， HAMAGUCHI Y， et al. Impact of sarcopenic obesity on outcomes in patients undergoing hepatectomy for hepatocellular carcinoma［J］. Ann Surg， 2019， 269（5）: 924-931.
17.FELICIANO E M C， KROENKE C H， MEYERHARDT J A， et al. Association of systemic inflammation and sarcopenia with survival in nonmetastatic colorectal cancer: results from the C SCANS study［J］. JAMA Oncol， 2017， 3（12）: e172319.
18.CAAN B J， CESPEDES FELICIANO E M， PRADO C M， et al. Association of muscle and adiposity measured by computed tomography with survival in patients with nonmetastatic breast cancer［J］. JAMA oncology， 2018， 4（6）: 798-804.
19.CHEN L K， WOO J， ASSANTACHAI P， et al. Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment［J］. J Am Med Dir Assoc， 2020， 21（3）: 300-307.
20.CRUZ-JENTOFT A J， SAYER A A. Sarcopenia［J］. Lancet， 2019， 393（10191）: 2636-2646.
21.MOURTZAKIS M， PRADO C M M， LIEFFERS J R， et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care［J］. Appl Physiol Nutr Metab， 2008， 33（5）: 997-1006.
22.ZHUANG C L， SHEN X， HUANG Y Y， et al. Myosteatosis predicts prognosis after radical gastrectomy for gastric cancer: a propensity score-matched analysis from a large-scale cohort［J］. Surgery， 2019， 166（3）: 297-304.
23.ONDER G， PENNINX B W J H， BALKRISHNAN R， et al. Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study［J］. Lancet， 2002， 359（9310）: 926-930.
24.DENT E， MORLEY J E， CRUZ-JENTOFT A J， et al. International Clinical Practice Guidelines for Sarcopenia （ICFSR）: screening， diagnosis and management［J］. J Nutr Health Aging， 2018， 22（10）: 1148-1161.
25.YAMAMOTO K， NAGATSUMA Y， FUKUDA Y， et al. Effectiveness of a preoperative exercise and nutritional support program for elderly sarcopenic patients with gastric cancer［J］. Gastric Cancer， 2017， 20（5）: 913-918.
26.CEREDA E， TURRI A， KLERSY C， et al. Whey protein isolate supplementation improves body composition， muscle strength， and treatment tolerance in malnourished advanced cancer patients undergoing chemotherapy［J］. Cancer Med， 2019， 8（16）: 6923-6932.
27.BAUER J M， VERLAAN S， BAUTMANS I， et al. Effects of a vitamin D and leucine-enriched whey protein nutritional supplement on measures of sarcopenia in older adults， the PROVIDE study: a randomized， double-blind， placebo-controlled trial［J］. J Am Med Dir Assoc， 2015， 16（9）: 740-747.
28.HOLEC∨EK M. Beta-hydroxy-beta-methylbutyrate supplementation and skeletal muscle in healthy and muscle-wasting conditions［J］. J Cachexia Sarcopenia Muscle， 2017， 8（4）: 529-541.
29.SHEA M K， FIELDING R A， DAWSON-HUGHES B. The effect of vitamin D supplementation on lower-extremity power and function in older adults: a randomized controlled trial［J］. Am J Clin Nutr， 2019， 109（2）: 369-379.
30.CHEUNG W W， HAO S， WANG Z， et al. Vitamin D repletion ameliorates adipose tissue browning and muscle wasting in infantile nephropathic cystinosis-associated cachexia［J］. J Cachexia Sarcopenia Muscle， 2019， 11（1）: 120-134
31.CRUZ-JENTOFT A J， DAWSON HUGHES B， SCOTT D， et al. Nutritional strategies for maintaining muscle mass and strength from middle age to later life: a narrative review［J］. Maturitas， 2020， 132: 57-64.
32.BURT L A， BILLINGTON E O， ROSE M S， et al. Effect of high-dose vitamin D supplementation on volumetric bone density and bone strength: a randomized clinical trial［J］. JAMA， 2019， 322（8）: 736-745.
33.CANDOW D G， FORBES S C， CHILIBECK P D， et al. Effectiveness of creatine supplementation on aging muscle and bone: focus on falls prevention and inflammation［J］. J Clin Med， 2019， 8（4）. pii: E488.
34.WYSS M， KADDURAH-DAOUK R. Creatine and creatinine metabolism［J］. Physiol Rev， 2000， 80（3）: 1107-1213.
35.TAN S， ZHOU F， LI N， et al. Anti-fatigue effect of ginsenoside Rb1 on postoperative fatigue syndrome induced by major small intestinal resection in rat［J］. Biol Pharm Bull， 2013， 36（10）: 1634-1639.
36.TAN S J， LI N， ZHOU F， et al. Ginsenoside Rb1 improves energy metabolism in the skeletal muscle of an animal model of postoperative fatigue syndrome［J］. J Surg Res， 2014， 191（2）: 344-349.
37.ZHUANG C L， MAO X Y， LIU S， et al. Ginsenoside Rb1 improves postoperative fatigue syndrome by reducing skeletal muscle oxidative stress through activation of the PI3K/Akt/Nrf2 pathway in aged rats［J］. Eur J Pharmacol， 2014， 740: 480-487.
38.CHEN W Z， LIU S， CHEN F F， et al. Prevention of postoperative fatigue syndrome in rat model by ginsenoside Rb1 via down-regulation of inflammation along the NMDA receptor pathway in the hippocampus［J］. Biol Pharm Bull， 2015， 38（2）: 239-247.
39.HUANG D D， FAN S D， CHEN X Y， et al. Nrf2 deficiency exacerbates frailty and sarcopenia by impairing skeletal muscle mitochondrial biogenesis and dynamics in an age-dependent manner［J］. Exp Gerontol， 2019， 119: 61-73.
40.CONTE E， CAMERINO G M， MELE A， et al. Growth hormone secretagogues prevent dysregulation of skeletal muscle calcium homeostasis in a rat model of cisplatin-induced cachexia［J］. J Cachexia Sarcopenia Muscle， 2017， 8: （3）: 386-404.
41.LA COLLA A， PRONSATO L， MILANESI L， et al. 17β-Estradiol and testosterone in sarcopenia: Role of satellite cells［J］. Ageing Res Rev， 2015， 24（Pt B）: 166-177.
42.WRIGHT T J， DILLON E L， DURHAM W J， et al. A randomized trial of adjunct testosterone for cancer-related muscle loss in men and women［J］. J Cachexia Sarcopenia Muscle， 2018， 9（3）: 482-496.